Optimization and biological evaluation of nicotinamide derivatives as Aurora kinase inhibitors

Add time:08/31/2019    Source:sciencedirect.com

Aurora kinases are known to be overexpressed in various solid tumors and implicated in oncogenesis and tumor progression. A series of nicotinamide derivatives were synthesized and their biological activities were evaluated, including kinase inhibitory activity against Aur A and Aur B and in vitro antitumor activity against SW620, HT-29, NCI-H1975 and Hela cancer cell lines. In addition, the study of antiproliferation, cytotoxicity and apoptosis was performed meanwhile. As the most potent inhibitor of Aur A, 4-((3-bromo-4-fluorophenyl)amino)-6-chloro-N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)-3-fluorophenyl)nicotinamide (10l) showed excellent antitumor activity against SW620 and NCI-H1975 with IC50 values were 0.61 and 1.06 μM, while the IC50 values of reference compound were 3.37 and 6.67 μM, respectively. Furthermore, binding mode studies indicated that compound 10l forms better interaction with Aur A.

We also recommend Trading Suppliers and Manufacturers of protein kinase inhibitor M (6-24) (cas 136058-51-0). Pls Click Website Link as below: cas 136058-51-0 suppliers

Prev:Potent and selective inhibitors of receptor-interacting protein kinase 1 that lack an aromatic back pocket group
Next:Synthesis and evaluation of new isatin-aminorhodanine hybrids as PIM1 and CLK1 kinase inhibitors)